CYBREXA THERAPEUTICS
Cybrexa Therapeutics is developing an entirely new class of small molecule DNA repair inhibitors that directly target the tumor microenvironment. This approach leverages a novel tumor-localizing peptide technology developed by an internationally recognized research laboratory at Yale. Our approach will change the paradigm of drug delivery, and it will greatly enhance the therapeutic index. It has the potential to re-define the definition of “drug-like,” which will unlock a vast array of molecules for clinical development. Our collection of tumor-localizing DNA repair inhibitors can be combined with numerous chemotherapies and also radiotherapy, allowing the safe delivery of higher drug doses, with enhanced efficacy.
CYBREXA THERAPEUTICS
Social Links:
Industry:
Biotechnology Pharmaceutical Therapeutics
Founded:
2017-01-01
Address:
New Haven, Connecticut, United States
Country:
United States
Website Url:
http://www.cybrexa.com
Total Employee:
1+
Status:
Active
Contact:
+1 860 717 2731
Total Funding:
44.4 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Google Font API Google Analytics Google Tag Manager WordPress Content Delivery Network Google Universal Analytics Wordpress Plugins
Similar Organizations
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Remedy Plan Therapeutics
Remedy Plan is a pre-clinical cancer therapeutics company developing first-in-class small molecule drugs that differentiate cancer cells.
Current Advisors List
Current Employees Featured
Founder
Investors List
Elm Street Ventures
Elm Street Ventures investment in Series B - Cybrexa Therapeutics
Advantage Capital
Advantage Capital investment in Series B - Cybrexa Therapeutics
HighCape Partners
HighCape Partners investment in Series B - Cybrexa Therapeutics
Cycle Venture Partners
Cycle Venture Partners investment in Series B - Cybrexa Therapeutics
HighCape Partners
HighCape Partners investment in Series B - Cybrexa Therapeutics
Connecticut Innovations
Connecticut Innovations investment in Series B - Cybrexa Therapeutics
Advantage Capital
Advantage Capital investment in Series B - Cybrexa Therapeutics
Advantage Capital
Advantage Capital investment in Debt Financing - Cybrexa Therapeutics
HighCape Partners
HighCape Partners investment in Series B - Cybrexa Therapeutics
Connecticut Innovations
Connecticut Innovations investment in Series B - Cybrexa Therapeutics
Official Site Inspections
http://www.cybrexa.com
- Host name: 172.67.158.9
- IP address: 172.67.158.9
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Cybrexa Therapeutics"
About - Cybrexa Therapeutics
Dr. Houston is President and Chief Executive Officer of Arvinas, Inc. Previously, he was the SVP of Specialty Discovery at Bristol-Myers Squibb (BMS). He spent more than 18 yearsSee details»
Cybrexa Therapeutics - Crunchbase Company Profile
Cybrexa Therapeutics is developing an entirely new class of small molecule DNA repair inhibitors that directly target the tumor microenvironment. This approach leverages a novel tumor-localizing peptide technology developed by an …See details»
Cybrexa Therapeutics Company Profile 2024: Valuation, Funding ...
Cybrexa Therapeutics General Information Description. Developer of oncology therapeutics designed for antigen-independent intracellular drug delivery. The company's therapeutics …See details»
Cybrexa, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Cybrexa Therapeutics Announces First Patient Dosed with First-in-Class Peptide-Drug Conjugate CBX-12 in Phase 2 Trial in Ovarian Cancer NEW HAVEN, Conn. – October 7, 2024 – Cybrexa …See details»
Cybrexa Therapeutics - Overview, News & Similar companies
Apr 12, 2023 Cybrexa Therapeutics To Present Data at ASCO 2023 Highlighting First-In-Human, Dose-Finding Study of Lead Candidate CBX-12 NEW HAVEN, Conn., May 25, 2023 …See details»
Cybrexa Therapeutics - Company Profile - Tracxn
Oct 13, 2024 Cybrexa Therapeutics ranks 266th among 2364 active competitors. 850 of its competitors are funded while 543 have exited. Overall, Cybrexa Therapeutics and its …See details»
Cybrexa Therapeutics - VentureRadar
Similar Companies: Aprea Sweden Privately Held Aprea Therapeutics, Inc. is a biopharmaceutical company headquartered in Boston, Massachusetts with research facilities in Stockholm, …See details»
Cybrexa Therapeutics - Contacts, Employees, Board Members
Organization. Cybrexa Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 5. Number of …See details»
Cybrexa, Inc. Company Profile | New Haven, CT - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Cybrexa, Inc. of New Haven, CT. Get the latest business insights from Dun & Bradstreet.See details»
Cybrexa Therapeutics - BioCT
Cybrexa plans to publish preclinical data for CBX-12 in the first half of 2020 and to advance the program into the clinic in 2021, with clinical efficacy and safety data expected by 2022. < …See details»
Cybrexa Therapeutics Closes $25 Million Series B Financing
Mar 10, 2021 Cybrexa was founded by physician-scientists and has an experienced management team that has built numerous successful life sciences companies. For more …See details»
Cybrexa raises $13.4M for first cancer drug trials
A New Haven biotech developing drugs that send cancer-fighting agents directly into tumor cells while sparing healthy tissue said it has raised $13.4 million. Cybrexa Therapeutics said it will …See details»
Exelixis and Cybrexa Therapeutics Establish Exclusive Collaboration ...
CBX-12 has potential to improve efficacy and reduce toxicity over systemic topoisomerase inhibitor Deal reflects Exelixis’ strategic focus on expanding its clinical pipeline and building …See details»
Cybrexa Therapeutics Enters Cooperative Research and
Feb 24, 2021 Cybrexa was founded by physician-scientists and has an experienced management team that has built numerous successful life sciences companies. For more …See details»
Cybrexa Regains Rights to CBX-12 - Yahoo Finance
Feb 6, 2024 Full rights returned to Cybrexa for CBX-12 effective April 25, 2024NEW HAVEN, Conn., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage …See details»
Cybrexa Therapeutics Announces Positive Final Data at ESMO …
Sep 16, 2024 Cybrexa is a privately held clinical-stage biotechnology company pioneering novel antigen-independent, tumor-targeting peptide drug conjugate (PDC) therapeutics. The …See details»
Cybrexa Therapeutics Announces Positive Final Data at ESMO …
Sep 16, 2024 Cybrexa Therapeutics. Data demonstrate broad activity of CBX-12 across six tumor types with a strong response rate in TOP1-naïve patients with ovarian (40%; N=10) and …See details»
Cybrexa Therapeutics Announces First Patient Dosed with First-in …
Oct 7, 2024 Primary target patient population for the CBX-12 Phase 2 study is women with platinum-resistant or refractory ovarian cancer who are naïve to TOP1-targeted agents Study …See details»
Ibexa and Raptor Announce Strategic Merger to Strengthen …
1 day ago Grégory Becue, Chief Growth Officer -- Oslo, January 13, 2025 -- Ibexa, a leading European provider of Digital Experience Platforms (DXP), is excited to announce a strategic …See details»
Cybrexa Therapeutics Announces First Patient Dosed with First-in …
Oct 7, 2024 Cybrexa plans an additional Phase 2 study of CBX-12 in colorectal cancer in 2025 in collaboration with the National Cancer Institute (NCI), as well as other Phase 2 studies …See details»